215 related articles for article (PubMed ID: 22166932)
1. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.
Lerose R; Musto P; Aieta M; Papa C; Tartarone A
Eur J Clin Pharmacol; 2012 May; 68(5):505-12. PubMed ID: 22166932
[TBL] [Abstract][Full Text] [Related]
2. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
[TBL] [Abstract][Full Text] [Related]
3. [Off-label use in oncology. The Italian choice].
Felicetti V; Gremigni U; Cifaldi L
Recenti Prog Med; 2008 Dec; 99(12):612-5. PubMed ID: 19388222
[TBL] [Abstract][Full Text] [Related]
4. Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016.
Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
Health Policy; 2019 Aug; 123(8):713-720. PubMed ID: 31277882
[TBL] [Abstract][Full Text] [Related]
5. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
6. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
7. The strange allure of state "right-to-try" laws.
Zettler PJ; Greely HT
JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
[No Abstract] [Full Text] [Related]
8. [Off-label therapy in rheumatology].
Krüger K; Sieper J
Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
[No Abstract] [Full Text] [Related]
9. [Pertinence of Off-label Prescriptions of Innovating and Expensive Drugs in a University Hospital].
Falabregues A; Daul M; Pourroy B; Gauthier-Villano L; Pisano P; Rathelot P; Vialettes B
Therapie; 2015; 70(5):385-402. PubMed ID: 26142399
[TBL] [Abstract][Full Text] [Related]
10. [HTA-Perspective: Challenges in the early assessment of new oncological drugs].
Wild C; Nachtnebel A
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):129-35. PubMed ID: 23663907
[TBL] [Abstract][Full Text] [Related]
11. The ethics of off-label use of drugs: oncology pharmacy in Italy.
Bernardi A; Pegoraro R
J Clin Pharm Ther; 2008 Apr; 33(2):95-9. PubMed ID: 18315773
[TBL] [Abstract][Full Text] [Related]
12. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
[No Abstract] [Full Text] [Related]
13. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
14. A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.
Messori A; Fadda V; Trippoli S
J Chemother; 2011 Apr; 23(2):67-70. PubMed ID: 21571620
[TBL] [Abstract][Full Text] [Related]
15. [Off-label therapy from the perspective of the medical insurance service].
Grell L; Rieger M
Z Rheumatol; 2012 Feb; 71(2):101-4, 106-7. PubMed ID: 22370800
[TBL] [Abstract][Full Text] [Related]
16. Japan works to shorten "drug lag," boost trials of new drugs.
Sinha G
J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
[No Abstract] [Full Text] [Related]
17. Off-label use of anti-cancer drugs in India: to be or not to be!
Gota V; Patial P
J Cancer Res Ther; 2011; 7(1):35-9. PubMed ID: 21546740
[TBL] [Abstract][Full Text] [Related]
18. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.
Kocs D; Fendrick AM
Am J Manag Care; 2003 May; 9(5):393-400; quiz 401-2. PubMed ID: 12744301
[TBL] [Abstract][Full Text] [Related]
19. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rothschedl E; Wild C; Simon J
Eur J Cancer; 2020 Apr; 129():23-31. PubMed ID: 32120272
[TBL] [Abstract][Full Text] [Related]
20. [Drug development in paediatric oncology].
Benninger-Döring G; Boos J
Klin Padiatr; 2006; 218(3):152-6. PubMed ID: 16688671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]